ArticleJournal of cellular biochemistry2008
Adeno-associated virus-mediated gene transfer.
Article in Journal of cellular biochemistry, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 34 citations in OpenAlex.
- Intravitreal Administration of AAV2-SIRT1 Reverses Diabetic Retinopathy in a Mouse Model of Type 2 Diabetes.Translational vision science & technology · 2023Article
- A directed evolution approach to select for novel Adeno-associated virus capsids on an HIV-1 producer T cell line.Journal of virological methods · 2017Article
- Efficient Gene Delivery and Expression in Pancreas and Pancreatic Tumors by Capsid-Optimized AAV8 Vectors.Human gene therapy methods · 2017Article
- Reprogramming Immune Response With Capsid-Optimized AAV6 Vectors for Immunotherapy of Cancer.Journal of immunotherapy (Hagerstown, Md. : 1997) · 2015Article
- Optogenetics.Current opinion in ophthalmology · 2015Review
- Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold?PloS one · 2013Article
- High-efficiency transduction of human monocyte-derived dendritic cells by capsid-modified recombinant AAV2 vectors.Vaccine · 2012Article
- Engineering humanized mice for improved hematopoietic reconstitution.Cellular & molecular immunology · 2012Review
- Sustained exendin-4 secretion through gene therapy targeting salivary glands in two different rodent models of obesity/type 2 diabetes.PloS one · 2012Article
- Recombinant AAV-directed gene therapy for type I glycogen storage diseases.Expert opinion on biological therapy · 2011Review
- Development of a successful antitumor therapeutic model combining in vivo dendritic cell vaccination with tumor irradiation and intratumoral GM-CSF delivery.Cancer immunology, immunotherapy : CII · 2011Article
- Evidence for the failure of adeno-associated virus serotype 5 to package a viral genome > or = 8.2 kb.Molecular therapy : the journal of the American Society of Gene Therapy · 2010Article
- Ex vivo magnetofection: a novel strategy for the study of gene function in mouse organogenesis.Developmental dynamics : an official publication of the American Association of Anatomists · 2009Article
- The SLC37 family of phosphate-linked sugar phosphate antiporters.Molecular aspects of medicineReview
- Targeted gene therapy for the treatment of heart failure.The Canadian journal of cardiologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Although the remarkable versatility and efficacy of recombinant adeno-associated virus 2 (AAV2) vectors in transducing a wide variety of cells and tissues in vitro, and in numerous pre-clinical animal models of human diseases in vivo, have been well established, the published literature is replete with controversies with regard to the efficacy of AAV2 vectors in hematopoietic stem cell (HSC) transduction. A number of factors have contributed to these controversies, the molecular bases of which have begun to come to light in recent years. With the availability of several novel serotypes (AAV1 through AAV12), rational design of AAV capsid mutants, and strategies (self-complementary vector genomes, hematopoietic cell-specific promoters), it is indeed becoming feasible to achieve efficient transduction of HSC by AAV vectors. Using a murine serial bone marrow transplantation model in vivo, we have recently documented stable integration of the proviral AAV genome into mouse chromosomes, which does not lead to any overt hematological abnormalities. Thus, a better understanding of the AAV-HSC interactions, and the availability of a vast repertoire of novel serotype and capsid mutant vectors, are likely to have significant implications in the use of AAV vectors in high-efficiency transduction of HSCs as well as in gene therapy applications involving the hematopoietic system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.